Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 672

1.

Clinical, Biochemical, Hematological, Endocrinological and Immunological Differences Between Graves' Disease Patients With and Without Thyroid Storm.

Yanai H, Hakoshima M, Katsuyama H.

J Clin Med Res. 2019 Jun;11(6):452-457. doi: 10.14740/jocmr3833. Epub 2019 May 10.

2.

Genome-Wide Association Study Confirming the Association of NAT2 with Susceptibility to Anti-tuberculosis Drug-Induced Liver Injury in Thai Patients.

Suvichapanich S, Wattanapokayakit S, Mushiroda T, Yanai H, Chuchottawon C, Kantima T, Suwankesawong W, Sonsupap C, Pannarunothai R, Tumpattanakul S, Bamrungram W, Chaiwong A, Mahasirimongkol S, Mameechai S, Panthong W, Klungtes N, Munsoo A, Chauychana U, Maneerat M, Fukunaga K, Omae Y, Tokunaga K.

Antimicrob Agents Chemother. 2019 May 20. pii: AAC.02692-18. doi: 10.1128/AAC.02692-18. [Epub ahead of print]

PMID:
31109976
3.

Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study.

Ben-Horin S, Lahat A, Amitai MM, Klang E, Yablecovitch D, Neuman S, Levhar N, Selinger L, Rozendorn N, Turner D, Chowers Y, Odes S, Schwartz D, Yanai H, Dotan I, Braun T, Haberman Y, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN).

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):519-528. doi: 10.1016/S2468-1253(19)30088-3. Epub 2019 May 9.

PMID:
31080097
4.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 May 6. pii: S0012-3692(19)30031-5. doi: 10.1016/j.chest.2019.01.011. [Epub ahead of print]

PMID:
31072612
5.

Cavernous hemangioma of the rib mimicking a chondrosarcoma: Diagnostic value of delayed phase MRI.

Tanaka T, Masaoka Y, Sugimoto S, Iguchi T, Hiraki T, Yanai H, Kanazawa S.

Diagn Interv Imaging. 2019 Apr 29. pii: S2211-5684(19)30089-0. doi: 10.1016/j.diii.2019.04.002. [Epub ahead of print] No abstract available.

PMID:
31047838
6.

Chemical Bonding in Polarised Push-Pull Ethylenes.

Yanai H, Suzuki T, Kleemiss F, Fukaya H, Dobashi Y, Malaspina LA, Grabowsky S, Matsumoto T.

Angew Chem Int Ed Engl. 2019 Jun 24;58(26):8839-8844. doi: 10.1002/anie.201904176. Epub 2019 May 24.

PMID:
31025431
7.

Streptococcal Infection Can Be the Trigger for Thyroid Storm.

Hakoshima M, Yanai H, Komatsuzaki S, Kawaguchi A, Hamasaki H, Katsuyama H.

J Clin Med Res. 2019 May;11(5):383-384. doi: 10.14740/jocmr3818. Epub 2019 Apr 14. No abstract available.

8.

High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

Kurozumi K, Nakano Y, Ishida J, Tanaka T, Doi M, Hirato J, Yoshida A, Washio K, Shimada A, Kohno T, Ichimura K, Yanai H, Date I.

Brain Tumor Pathol. 2019 Apr 22. doi: 10.1007/s10014-019-00345-y. [Epub ahead of print]

PMID:
31011918
9.

Associations of Pericardial Fat Area Determined by Routine Chest Computed Tomography With Coronary Risk Factors and Coronary Artery Disease.

Yoshikawa R, Yanai H, Moriyama S, Furugaki N.

J Clin Med Res. 2019 Apr;11(4):289-296. doi: 10.14740/jocmr3782. Epub 2019 Mar 18.

10.

Epstein-Barr virus detection using gastric biopsy specimens after rapid urease test for Helicobacter pylori.

Yanai H, Iizasa H, Chihara D, Murakami T, Nishikawa J, Yoshiyama H.

Endosc Int Open. 2019 Apr;7(4):E431-E432. doi: 10.1055/a-0859-7233. Epub 2019 Mar 21. No abstract available.

11.

Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives.

Yanai H, Yoshida H.

Int J Mol Sci. 2019 Mar 8;20(5). pii: E1190. doi: 10.3390/ijms20051190. Review.

12.

Does Metformin Assist New Anti-Diabetic Drugs to Succeed?

Kastuyama H, Yanai H.

J Clin Med Res. 2019 Feb;11(2):151-155. doi: 10.14740/jocmr3706. Epub 2019 Jan 5. No abstract available.

13.

Validity of visceral fat area measurement by bioelectrical impedance analysis in Japanese obese individuals.

Hamasaki H, Furuta M, Yanai H.

Curr Diabetes Rev. 2019 Jan 27. doi: 10.2174/1573399815666190128113657. [Epub ahead of print]

PMID:
30686247
14.

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors.

Yanai H, Adachi H, Hakoshima M, Katsuyama H.

J Clin Med Res. 2019 Jan;11(1):76-79. doi: 10.14740/jocmr3676. Epub 2018 Dec 3. No abstract available.

15.

Dermoid cyst presenting as an intramuscular mass: CT and MRI features.

Tanaka T, Inai R, Iguchi T, Yanai H, Kanazawa S.

Diagn Interv Imaging. 2019 Mar;100(3):195-196. doi: 10.1016/j.diii.2018.12.001. Epub 2018 Dec 19. No abstract available.

PMID:
30579768
16.

Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.

Mitsui Y, Sadahira T, Maruyama Y, Wada K, Tanimoto R, Sugimoto M, Araki M, Watanabe M, Yanai H, Watanabe T, Nasu Y.

Acta Med Okayama. 2018 Dec;72(6):605-609. doi: 10.18926/AMO/56380.

17.

Starch Consumption May Modify Antiglycan Antibodies and Fecal Fungal Composition in Patients With Ileo-Anal Pouch.

Goren I, Godny L, Reshef L, Yanai H, Gophna U, Tulchinsky H, Dotan I.

Inflamm Bowel Dis. 2019 Mar 14;25(4):742-749. doi: 10.1093/ibd/izy370.

PMID:
30535148
18.
19.

Which Nutritional Factors Are Good for HDL?

Yanai H, Tada N.

J Clin Med Res. 2018 Dec;10(12):936-939. doi: 10.14740/jocmr3646. Epub 2018 Oct 30. No abstract available.

20.

Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease - feasibility study.

Eliakim R, Spada C, Lapidus A, Eyal I, Pecere S, Fernández-Urién I, Lahat A, Costamagna G, Schwartz A, Ron Y, Yanai H, Adler S.

Endosc Int Open. 2018 Oct;6(10):E1235-E1246. doi: 10.1055/a-0677-170. Epub 2018 Oct 8.

21.

Genotype-Serotype Interactions Shed Light on Genetic Components of Inflammatory Bowel Diseases.

Ben-Shachar S, Finezilber Y, Elad H, Rabinowitz K, Goren I, Isakov O, Yanai H, Dotan I.

Inflamm Bowel Dis. 2019 Jan 10;25(2):336-344. doi: 10.1093/ibd/izy231.

PMID:
30265311
22.

A Different Effect of an Orexin Receptor Antagonist on Metabolic Parameters Between Diabetic Patients and Non-Diabetic Patients.

Yanai H, Moriyama S.

J Clin Med Res. 2018 Oct;10(10):795. doi: 10.14740/jocmr3537w. Epub 2018 Sep 10. No abstract available.

23.

Quality indicators for cervical cancer care in Japan.

Watanabe T, Mikami M, Katabuchi H, Kato S, Kaneuchi M, Takahashi M, Nakai H, Nagase S, Niikura H, Mandai M, Hirashima Y, Yanai H, Yamagami W, Kamitani S, Higashi T.

J Gynecol Oncol. 2018 Nov;29(6):e83. doi: 10.3802/jgo.2018.29.e83.

24.

Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.

Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, Ungar B, Schwartz D, Zittan E, Openhaim M, Yanai H, Maharshak N, Bar Gil Shitrit A, Naftali T, Eliakim R, Chowers Y, Ben-Horin S, Dotan I.

Dig Liver Dis. 2019 Jan;51(1):68-74. doi: 10.1016/j.dld.2018.07.040. Epub 2018 Aug 10.

PMID:
30172649
25.

Habit of Bathing or Showering Is Beneficially Associated With Body Weight and Abdominal Circumference in Patients With Type 2 Diabetes.

Katsuyama H, Hamasaki H, Yanai H.

J Clin Med Res. 2018 Sep;10(9):728-731. doi: 10.14740/jocmr3510w. Epub 2018 Jul 31. No abstract available.

26.

Evidence for Host-Bacterial Co-evolution via Genome Sequence Analysis of 480 Thai Mycobacterium tuberculosis Lineage 1 Isolates.

Palittapongarnpim P, Ajawatanawong P, Viratyosin W, Smittipat N, Disratthakit A, Mahasirimongkol S, Yanai H, Yamada N, Nedsuwan S, Imasanguan W, Kantipong P, Chaiyasirinroje B, Wongyai J, Toyo-Oka L, Phelan J, Parkhill J, Clark TG, Hibberd ML, Ruengchai W, Palittapongarnpim P, Juthayothin T, Tongsima S, Tokunaga K.

Sci Rep. 2018 Aug 2;8(1):11597. doi: 10.1038/s41598-018-29986-3.

27.

Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.

Kimura Y, Negishi H, Matsuda A, Endo N, Hangai S, Inoue A, Nishio J, Taniguchi T, Yanai H.

Cancer Sci. 2018 Sep;109(9):2687-2696. doi: 10.1111/cas.13726. Epub 2018 Aug 1.

28.

Bofutsushosan Significantly Ameliorated Betamethasone-Induced Cushing's Syndrome.

Yanai H.

J Clin Med Res. 2018 Aug;10(8):668-669. doi: 10.14740/jocmr3483w. Epub 2018 Jun 27. No abstract available.

29.

Autoimmune Polyendocrine Syndromes.

Yanai H.

N Engl J Med. 2018 Jun 28;378(26):2542-3. doi: 10.1056/NEJMc1805308. No abstract available.

PMID:
29952181
30.

Which Factor Determines the Duration Required for Relief of Glucotoxicity by the Intensive Insulin Therapy?

Yanai H, Hakoshima M, Adachi H.

J Clin Med Res. 2018 Jul;10(7):606-608. doi: 10.14740/jocmr3423w. Epub 2018 Jun 4. No abstract available.

31.

Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer.

Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K, Suehiro Y, Yamasaki T, Sakaida I.

Cancers (Basel). 2018 May 29;10(6). pii: E167. doi: 10.3390/cancers10060167. Review.

32.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.

PMID:
29788318
33.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.

Suvichapanich S, Fukunaga K, Zahroh H, Mushiroda T, Mahasirimongkol S, Toyo-Oka L, Chaikledkaew U, Jittikoon J, Yuliwulandari R, Yanai H, Wattanapokayakit S, Tokunaga K.

Pharmacogenet Genomics. 2018 Jul;28(7):167-176. doi: 10.1097/FPC.0000000000000339.

PMID:
29781872
34.

Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers.

Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S.

Oncotarget. 2018 Apr 24;9(31):21844-21860. doi: 10.18632/oncotarget.25074. eCollection 2018 Apr 24.

35.

Synthesis and Characterization of Stable Phosphorus Carbabetaines.

Yanai H, Almendros P, Takahashi S, Lázaro-Milla C, Alcaide B, Matsumoto T.

Chem Asian J. 2018 May 17. doi: 10.1002/asia.201800769. [Epub ahead of print]

PMID:
29771003
36.

Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes.

Nakamura R, Inage Y, Tobita R, Yoneyama S, Numata T, Ota K, Yanai H, Endo T, Inadome Y, Sakashita S, Satoh H, Yuzawa K, Terashima T.

J Thorac Oncol. 2018 Jul;13(7):895-903. doi: 10.1016/j.jtho.2018.04.035. Epub 2018 May 8.

PMID:
29751134
37.

β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma).

Suzuki Y, Ichihara S, Kawasaki T, Yanai H, Kitagawa S, Shimoyama Y, Nakamura S, Nakaguro M.

Virchows Arch. 2018 Aug;473(2):235-239. doi: 10.1007/s00428-018-2370-9. Epub 2018 May 7.

PMID:
29736797
38.

Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice.

Yanai H, Chiba S, Hangai S, Kometani K, Inoue A, Kimura Y, Abe T, Kiyonari H, Nishio J, Taguchi-Atarashi N, Mizushima Y, Negishi H, Grosschedl R, Taniguchi T.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5253-5258. doi: 10.1073/pnas.1803936115. Epub 2018 Apr 30.

39.

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

Hakoshima M, Yanai H, Kakuta K, Adachi H.

J Clin Med Res. 2018 Jun;10(6):493-498. doi: 10.14740/jocmr3392w. Epub 2018 Apr 13.

40.

Effects of an orexin receptor antagonist on blood pressure and metabolic parameters.

Moriyama S, Yanai H, Takeuchi Y, Hayakawa T.

J Clin Hypertens (Greenwich). 2018 May;20(5):978-980. doi: 10.1111/jch.13288. Epub 2018 Apr 27. No abstract available.

41.

Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis.

Iny O, Yanai H, Matalon S, Santo E, Shibolet O, Dotan I, Maharshak N.

Isr Med Assoc J. 2018 Jan;20(1):25-29.

42.

Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.

Takamoto A, Tanimoto R, Bekku K, Araki M, Sadahira T, Wada K, Ebara S, Katayama N, Yanai H, Nasu Y.

Int J Urol. 2018 May;25(5):507-512. doi: 10.1111/iju.13555. Epub 2018 Apr 12.

43.

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.

Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, Weisshof R, Goren I, Rabinowitz K, Waterman M, Yanai H, Dotan I, Sabo E, Chowers Y, Khatri P, Shen-Orr SS; Israeli IBD research Network (IIRN).

Gut. 2019 Apr;68(4):604-614. doi: 10.1136/gutjnl-2017-315494. Epub 2018 Apr 4.

44.

Exercise Therapy for Patients With Type 2 Diabetes: A Narrative Review.

Yanai H, Adachi H, Masui Y, Katsuyama H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T, Hamasaki H, Sako A.

J Clin Med Res. 2018 May;10(5):365-369. doi: 10.14740/jocmr3382w. Epub 2018 Mar 16. Review.

45.

An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids.

Yanai H, Masui Y, Katsuyama H, Adachi H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T, Sako A.

J Clin Med Res. 2018 Apr;10(4):281-289. doi: 10.14740/jocmr3362w. Epub 2018 Feb 18. Review.

46.

Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes.

Yanai H.

Ann Transl Med. 2017 Dec;5(23):470. doi: 10.21037/atm.2017.09.22. No abstract available.

47.

Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03).

Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, Iwamoto Y, Kajio H, Yanai H, Mishima S, Handa N, Shimokawa K, Yoshida A, Watanabe H, Ohe K, Shimbo T, Noda M.

Intern Med. 2018 May 1;57(9):1229-1240. doi: 10.2169/internalmedicine.9481-17. Epub 2017 Dec 27.

48.

Gastric neuroendocrine tumor arising from heterotopic pancreas.

Tanaka T, Omote R, Okazaki N, Yanai H, Yoshino T.

Clin J Gastroenterol. 2018 Feb;11(1):34-37. doi: 10.1007/s12328-017-0795-3. Epub 2017 Dec 7.

49.

Understanding of hypertension and heart failure in patients with type 2 diabetes by studying effects of sodium-glucose cotransporter 2 inhibitors on plasma B-type natriuretic peptide levels.

Yanai H, Adachi H, Hakoshima M.

J Clin Hypertens (Greenwich). 2018 Feb;20(2):411-412. doi: 10.1111/jch.13174. Epub 2017 Dec 1. No abstract available.

50.

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.

Koguchi A, Adachi H, Yanai H.

J Clin Med Res. 2017 Dec;9(12):1029-1031. doi: 10.14740/jocmr3220w. Epub 2017 Nov 6. No abstract available.

Supplemental Content

Support Center